Bastide Completes the Sale of Experf to Italian Group Sapio
On Monday, Bastide Group announced the completion of the sale of its subsidiary New Medical Concept, the holding company of Experf Group (home infusion and nutrition), to the Italian group Sapio. The agreement signed on May 21 lifted all its suspensive conditions at the end of the month.
The finalization of this divestiture is part of a restructuring of Bastide Group's portfolio of activities. The operation is in line with the company's desire to focus its resources on areas considered most strategic and with higher added value, according to the press release. Vincent Bastide, CEO of the group, believes that this sale allows to 'crystallize the value created since the integration of Experf into the group' and to 'strengthen our financial structure'.
Sapio Strengthens Its Presence in France
For Sapio Group, this acquisition is a key step in its European expansion strategy. The Italian multinational, present in industrial and medical gases and home care services, plans to leverage Experf's territorial network in France to continue its growth in the home health services sector. Its presence in France will reach more than 140 million euros in revenue through this operation, complementing its existing structures Homeperf, Synapse Santé, and Synartis. According to the source, Sapio's total revenue is expected to exceed 1 billion euros once the acquisition is completed.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Context
Period
Period: T1 2027
Key reported figures
Revenue: 124,3 millions d'euros
Quarterly revenue: 124,3 millions d'euros
Revenue growth: 7,5 %
Guidance from the release
The Group's Q1 performance confirms the strength of its business momentum and its full confidence in achieving its full-year targets
Opportunities identified
International markets showing very strong momentum with growth of nearly 20%, driven by Oxystore Italy and Intus UK performances
Diabetes business recorded growth of more than 20% with positive volume and pricing effects
Respiratory care maintained strong momentum at 10.6% growth supported by structural market growth and market share gains
Outlook / guidance
Expected revenue: 500 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.